Canada markets close in 6 hours 11 minutes

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.2350+0.0350 (+2.92%)
As of 09:49AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.2000
Open1.2250
Bid1.2100 x 1200
Ask1.2200 x 41800
Day's Range1.2100 - 1.2500
52 Week Range1.1650 - 4.9100
Volume1,487,270
Avg. Volume20,517,598
Market Cap2.56B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2200
Earnings DateMar 01, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.59
  • GlobeNewswire

    Cronos Group Reports 2022 Fourth Quarter and Full-Year Results

    Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash and short-term investments Spinach® became the number one edible brand

  • GlobeNewswire

    Ginkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants

    The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airportsBOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention’s (CDC’s) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV

  • GlobeNewswire

    Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports

    Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec